Your browser doesn't support javascript.
Association of Trends in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Seroprevalence and State-Issued Nonpharmaceutical Interventions: United States, 1 August 2020 to 30 March 2021.
Miller, Maureen J; Himschoot, Austin; Fitch, Natalie; Jawalkar, Sucheta; Freeman, Dane; Hilton, Charity; Berney, Kevin; Guy, Gery P; Benoit, Tina J; Clarke, Kristie E N; Busch, Michael P; Opsomer, Jean D; Stramer, Susan L; Hall, Aron J; Gundlapalli, Adi V; MacNeil, Adam; McCord, Russell; Sunshine, Gregory; Howard-Williams, Mara; Dunphy, Christopher; Jones, Jefferson M.
  • Miller MJ; CDC COVID-19 Response, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Himschoot A; Georgia Tech Research Institute, Atlanta, Georgia, USA.
  • Fitch N; Georgia Tech Research Institute, Atlanta, Georgia, USA.
  • Jawalkar S; Georgia Tech Research Institute, Atlanta, Georgia, USA.
  • Freeman D; Georgia Tech Research Institute, Atlanta, Georgia, USA.
  • Hilton C; Georgia Tech Research Institute, Atlanta, Georgia, USA.
  • Berney K; Geospatial Research, Analysis, and Services Program (GRASP), Agency for Toxic Substances and Disease Registry, CDC, Atlanta, Georgia, USA.
  • Guy GP; CDC COVID-19 Response, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Benoit TJ; CDC COVID-19 Response, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Clarke KEN; CDC COVID-19 Response, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Busch MP; Vitalant Research Institute, San Francisco, California, USA.
  • Opsomer JD; Westat, Inc, Rockville, Maryland, USA.
  • Stramer SL; Scientific Affairs, American Red Cross, Gaithersburg, Maryland, USA.
  • Hall AJ; CDC COVID-19 Response, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Gundlapalli AV; CDC COVID-19 Response, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • MacNeil A; CDC COVID-19 Response, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • McCord R; CDC COVID-19 Response, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Sunshine G; CDC COVID-19 Response, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Howard-Williams M; CDC COVID-19 Response, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Dunphy C; CDC COVID-19 Response, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Jones JM; CDC COVID-19 Response, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
Clin Infect Dis ; 75(Supplement_2): S264-S270, 2022 Oct 03.
Article in English | MEDLINE | ID: covidwho-2051340
ABSTRACT

BACKGROUND:

We assess if state-issued nonpharmaceutical interventions (NPIs) are associated with reduced rates of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection as measured through anti-nucleocapsid (anti-N) seroprevalence, a proxy for cumulative prior infection that distinguishes seropositivity from vaccination.

METHODS:

Monthly anti-N seroprevalence during 1 August 2020 to 30 March 2021 was estimated using a nationwide blood donor serosurvey. Using multivariable logistic regression models, we measured the association of seropositivity and state-issued, county-specific NPIs for mask mandates, gathering bans, and bar closures.

RESULTS:

Compared with individuals living in a county with all three NPIs in place, the odds of having anti-N antibodies were 2.2 (95% confidence interval [CI] 2.0-2.3) times higher for people living in a county that did not have any of the 3 NPIs, 1.6 (95% CI 1.5-1.7) times higher for people living in a county that only had a mask mandate and gathering ban policy, and 1.4 (95% CI 1.3-1.5) times higher for people living in a county that had only a mask mandate.

CONCLUSIONS:

Consistent with studies assessing NPIs relative to COVID-19 incidence and mortality, the presence of NPIs were associated with lower SARS-CoV-2 seroprevalence indicating lower rates of cumulative infections. Multiple NPIs are likely more effective than single NPIs.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Humans Country/Region as subject: North America Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: Cid

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Humans Country/Region as subject: North America Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: Cid